<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Recreated Figure</title>
    <style>
        body {
            font-family: sans-serif;
            line-height: 1.6;
            margin: 20px;
            font-size: 18px; /* Increased base font size */
        }
        .container {
            display: flex;
            flex-wrap: wrap;
            gap: 20px;
        }
        .column {
            flex: 1;
            min-width: 400px;
            padding: 20px;
            border-radius: 8px;
        }
        .left-column {
            background-color: #F2FFF5; /* Very light green, closer to original */
            border: 1px solid #D9F2DD; /* Softer green border */
        }
        .right-column {
            background-color: #F2F9FF; /* Very light blue, closer to original */
            border: 1px solid #D9EFFF; /* Softer blue border */
        }
        h2 {
            font-size: 1.8em; /* Larger heading */
            margin-top: 0;
            border-bottom: 2px solid #ccc;
            padding-bottom: 0.3em;
        }
        h3 {
            font-size: 1.4em; /* Larger subheading */
            margin-top: 1.5em;
            margin-bottom: 0.5em;
        }
        p, li {
            font-size: 1.1em; /* Larger paragraph/list item text */
        }
        ul {
            padding-left: 20px;
        }
        table {
            width: 100%;
            border-collapse: collapse;
            margin-top: 1em;
            font-size: 1em; /* Adjusted table font size relative to body */
        }
        th, td {
            border: 1px solid #ddd;
            padding: 8px;
            text-align: left;
        }
        th {
            background-color: #f2f2f2;
        }
        .icon {
            margin-right: 8px;
        }
        .question-box {
            background-color: #fff;
            padding: 15px;
            border-radius: 5px;
            margin-bottom: 15px;
            border: 1px solid #eee;
        }
        .answer-box {
            background-color: #f9f9f9;
            padding: 10px;
            border-radius: 5px;
            margin-top: 5px;
            border: 1px solid #e0e0e0;
            font-weight: bold;
        }
        .left-column h2 .icon {
            color: #28a745; /* Green icon */
        }
        .right-column h2 .icon {
            color: #007bff; /* Blue icon */
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="column left-column">
            <h2><span class="icon">üíª</span>Computer Use Agent Questions</h2>

            <div class="question-box">
                <h3>Base Question:</h3>
                <p>"On Hemonc.org, find/search the clinical trial id that best describes the efficacy of Lenalidomide monotherapy compared to Erythropoetin beta and Lenalidomide when used to treat Myelodysplastic syndrome."</p>
                <p><strong>Output format:</strong> NCT<Number></p>
            </div>

            <div class="question-box">
                <h3>Extended Questions:</h3>
                <ul>
                    <li>Track_second_authors</li>
                    <li>Track_pmids</li>
                    <li>Track_start_date</li>
                </ul>
            </div>

            <div class="question-box">
                <h3><span class="icon">üåç</span>Website Ground Truth</h3>
                <p><strong>Website link:</strong> <a href="https://hemonc.org/wiki/Myelodysplastic_syndrome" target="_blank">https://hemonc.org/wiki/Myelodysplastic_syndrome</a></p>
                <h4>Regimen variant #2</h4>
                <table>
                    <thead>
                        <tr>
                            <th>Study</th>
                            <th>Dates of enrollment</th>
                            <th>Evidence</th>
                            <th>Comparator</th>
                            <th>Comparative Efficacy</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>List et al. 2021 (ECOG E2905)</td>
                            <td>2009-2016</td>
                            <td>Phase 3 (E-esc)</td>
                            <td>Lenalidomide</td>
                            <td>Higher major erythroid response (primary endpoint)</td>
                        </tr>
                        <tr>
                            <td>Toma et al. 2015 (GFM-Len-Epo-08)</td>
                            <td>2010-2012</td>
                            <td>Phase 3 (E-esc)</td>
                            <td>Lenalidomide</td>
                            <td>Seems to have better erythroid response per IWG 2006 criteria (primary endpoint)</td>
                        </tr>
                    </tbody>
                </table>
                <p><small>Note: patients in ECOG E2905 were reassessed after cycle 4 and discontinued treatment if they did not have a MER.</small></p>
                <p><strong>Biomarker eligibility criteria:</strong></p>
                <ul>
                    <li>Absence of del(5q)</li>
                </ul>
                <p><strong>Targeted therapy:</strong></p>
                <ul>
                    <li>Lenalidomide (Revlimid) 10 mg PO once per day on days 1 to 21</li>
                </ul>
                <p><strong>Growth factor therapy:</strong></p>
                <ul>
                    <li>Epoetin beta (Recormon) 60,000 units SC once per day on days 1, 8, 15, 22</li>
                </ul>
                <p>28-day cycles</p>
            </div>

            <div class="question-box">
                <h3><span class="icon">üí¨</span>Additional Context</h3>
                <p>Follow-up queries expand on the clinical trial data to trace connections between authors, publications, and timeline information.</p>
            </div>
        </div>

        <div class="column right-column">
            <h2><span class="icon">üîç</span>Deep Research Questions</h2>

            <div class="question-box">
                <h3><span class="icon">‚è∞</span>Hop 1: Clinical Trial Ingredient</h3>
                <p>"For clinical trial NCT00843882, among the more effective regimen ingredients, find which ingredient starts with the letter 'L'."</p>
                <div class="answer-box">INGREDIENT: LENALIDOMIDE</div>
            </div>

            <div class="question-box">
                <h3><span class="icon">üìÑ</span>Hop 2: Company with Latest FDA Approval</h3>
                <p>"Then, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient."</p>
                <div class="answer-box">
                    COMPANY: CELGENE CORPORATION<br>
                    (Part of BRISTOL MYERS SQUIBB)
                </div>
            </div>

            <div class="question-box">
                <h3><span class="icon">üìÖ</span>Hop 3: Patent Expiration Date</h3>
                <p>"Then, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?"</p>
                <div class="answer-box">DATE: Apr 27, 2027</div>
            </div>

            <div class="question-box">
                <h3><span class="icon">üîë</span>Hop 4: FDA Exclusivity Date</h3>
                <p>"Then, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?"</p>
                <div class="answer-box">DATE: 5/28/2026</div>
            </div>

            <div class="question-box">
                <h3><span class="icon">üìà</span>Hop 5: Stock Market Data</h3>
                <p>"If this company is listed on any US stock market, provide: 1. The stock ticker symbol 2. The opening stock price on the FDA approval date"</p>
                <div class="answer-box">
                    TICKER: BMY (Bristol Myers Squibb)<br>
                    OPENING PRICE: $46.73
                </div>
            </div>
        </div>
    </div>
</body>
</html>
